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Covalent inhibitors: a rational approach to drug
discovery
Fandi Sutanto, Markella Konstantinidou and Alexander Dömling *
Covalent inhibitors are recognized as an important component in drug discovery and therapeutics. Since
the first appearance of covalent inhibitors in the late 18th century, the field has advanced significantly and
currently about 30% of the marketed drugs are covalent inhibitors. The numerous advantages of covalent
inhibitors are counteracting the initial concerns regarding potential off-target toxicity. Thus, continuous
research, especially for cancer targets is reported. The aim of this review is to provide a short historic
overview and focus on recently developed covalent inhibitors (2011–2019), including structural aspects and
examples on challenging targets.
1. Introduction
Traditionally, drug design of small molecules is based on
their ability to interact with their biological targets under
equilibrium binding states. These binding states occur in a
fast and reversible process, which affects the duration of the
therapeutic response. Thus, prolongation of therapeutic
response can be extended by increasing the duration of
interaction between a drug and its target. This type of
prolonged interaction can be achieved by covalent inhibitors.
Covalent inhibitors bind to their target in two steps, starting
with equilibrium bond formation, and ending with covalent
bond formation. The final state is considered to be
irreversible, resulting in a drug–protein complex that is
different from that formed with a normal equilibrium bond
(Fig. 1).
Covalent inhibitors in general are compounds that by
design are intended to form a covalent bond with a specific
molecular target. The covalent bond can be either reversible
or irreversible, depending on the chosen warhead. A number
of different warheads have been exploited to target specific
amino acid residues, including among others cysteine,
serine, threonine, tyrosine and lysine. A detailed overview of
covalent warheads, as well as the amino acids that they target
was recently published.1
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Despite the initial skepticism of pharmaceutical industry
to develop covalent inhibitors, in the last 50 years, the
development of covalent inhibitors has shown a significant
increase (Fig. 2).2,3 Numerous drug candidates are
progressing through clinical trials or being approved by the
FDA. Today, there are at least 50 FDA-approved drugs that act
as covalent inhibitors.
Due to the growing interest in covalent inhibitors as
drugs, it is worthwhile to examine the design of these drugs
in detail. In this review, after a short historic overview, the
advantages and disadvantages of covalent inhibitors are
discussed. Then, we focus on covalent inhibitors that reached
the market or are in advanced clinical trials (2011–2019). In
the last part, we review recent applications of covalent
inhibitors.
2. Historic background of covalent
inhibitors
The earliest covalent inhibitor to be introduced was
acetylsalicylic acid (aspirin), which has been marketed since
1899 (Fig. 3). The acetyl warhead of aspirin acetylates Ser-530
of prostaglandin endoperoxide (PGH) synthase-1, inactivating
the cyclooxygenase activity of the enzyme.4 Penicillin, which
was discovered in 1928, also acts as a covalent inhibitor, as
the β-lactam binds covalently to the active site serine (Ser-36)
of the bacterial enzyme DD-transpeptidase to form penicilloyl-
enzyme which is inactive, thus making it incapable of
synthesizing the cell-wall.5
In 1975, timoprazole showed inhibition towards gastric
acid secretion.6 However, due to its toxicity, the development
of timoprazole was stopped. Its derivative, omeprazole, was
discovered in 1979, as the first class of drug which is now
known as proton pump inhibitor (PPI).7,8 Omeprazole forms
a disulfide bond with the sulfhydryl group of the hydrogen–
potassium ATPase. The second of the PPI drugs to reach the
market was lansoprazole, which was patented in 1984,
launched in early 1990s, and approved by FDA in 1995.
In the 1990s, two examples of the most successful covalent
drugs were fosfomycin and clopidogrel. Fosfomycin was
found in 1969,9 however, the approval and medical usage
started in 1996. The drug inhibits bacterial cell wall
biogenesis through inactivation of the enzyme MurA.10 It
bears an epoxide warhead, which is targeting the active site
residue Cys-115 of MurA. Clopidogrel was patented in 1982,
and approved for medical use in 1997. Clopidogrel is a
prodrug, which is used as antiplatelet medication. The
prodrug undergoes a two-step metabolic activation; the
thiophene ring is first oxidized towards the inactive in vitro
2-oxo-clopidogrel and then by ring opening, the active thiol–
carboxylic acid metabolite is released. The latter binds
irreversibly via the –SH group to the P2Y21 purinergic
receptor, thus preventing binding of ADP to the P2Y21
receptor. Bortezomib, one of the few covalent inhibitors with
boronic acid warhead, is an anticancer medication. It was
approved and marketed in 2003. In 2009, a drug containing
nitrile warhead saxagliptin was developed. Saxagliptin is an
antidiabetic drug which was used to treat type 2 diabetes
Fig. 1 General mechanism of covalent interaction between a small
molecule and its target.
Fig. 2 Number of publications per decade obtained from a search of
the term “covalent drug” in SciFinder®.
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mellitus, succeeding vildagliptin which was withdrawn in
2008. Today, there are at least 50 approved covalent
inhibitors used to treat ailments ranging from obesity to
cancer.3 Zanubrutinib (approved November 2019, brand
name Brukinsa®) and dacomitinib (approved September
2018, marketed under the name Vizimpro®) are two of the
most recently approved covalent inhibitors of BTK and EGFR,
respectively.
3. Advantages and disadvantages of
covalent inhibitors
Toxicity and efficacy are the main reasons for the attrition of
drug candidates during clinical study.11 In these regards,
covalent inhibitors have several advantages: (1) improving
efficiency, (2) lowering the dose, (3) increasing compliance
Fig. 3 A historic overview of covalent inhibitors and their approval dates. The warheads are highlighted in red.
Fig. 4 Approved covalent drugs by therapeutic indication.




1. Telaprevir Anti-HCV α-Ketoamide 2011
2. Boceprevir Anti-HCV α-Ketoamide 2011
3. Abiraterone Anticancer — 2011






6. Ibrutinib Anticancer α,β-Unsaturated carbonyl 2014
7. Osimertinib Anticancer α,β-Unsaturated carbonyl 2015
8. Olmutinib Anticancer α,β-Unsaturated carbonyl 2015
9. Narlaprevir Anti-HCV α-Ketoamide 2016
10. Acalabrutinib Anticancer α,β-Unsaturated
propargylamide
2017
11. Neratinib Anticancer α,β-Unsaturated carbonyl 2017
12. Dacomitinib Anticancer α,β-Unsaturated carbonyl 2018
13. Selinexor Anticancer α,β-Unsaturated carbonyl 2019
14. Zanubrutinib Anticancer α,β-Unsaturated carbonyl 2019
Fig. 5 Abiraterone complex with human cytochrome P450 CYP17A1
(PDB ID 3RUK). Abiraterone is shown as cyan sticks and HEM-600 is
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Fig. 7 Chemical structures and binding modes with the target protein: (a) dimethyl fumarate binding to Cys-599 (PDB ID 5O1S), (b) EGFR kinase
inhibitor dacomitinib, binding Cys-797 (PDB ID 4I24), (c) ibrutinib (PDB ID 5P9J), and (d) zanubrutinib (PDB ID 6J6M) binding to Cys-481 of BTK.
Inhibitors are shown as cyan sticks and Cys-599, Cys-797, Cys-481 are shown as yellow sticks.
Fig. 6 Chemical structures of covalent inhibitors and their crystal structures with the NS3/4A protease complex (a) telaprevir binding to Ser-1139
(PDB ID 3SV6), (b) narlaprevir (PDB ID 3LON), and (c) boceprevir (PDB ID 3LOX) binding to Ser-139. Inhibitors are shown as cyan sticks and Ser-
1139, Ser-139 are shown as yellow sticks.
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Table 2 Examples of covalent inhibitors in clinical trials
No. Structure and name Target (therapeutic) Warhead Clinical stage
1
PRN1008
BTK inhibitor α,β-Unsaturated carbonyl III
2
Evobrutinib
BTK inhibitor α,β-Unsaturated carbonyl III
3
AMG510
KRAS inhibitor α,β-Unsaturated carbonyl II
4
Poziotinib
EGFR inhibitor α,β-Unsaturated carbonyl II
5
PF-06651600
JAK3 inhibitor α,β-Unsaturated carbonyl II
6
Remibrutinib
BTK inhibitor α,β-Unsaturated carbonyl II
7
Futibatinib
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due to less-frequent dosing, (4) reducing the possibility of
drug resistance, and (5) targeting shallow binding sites. Each
of these advantages is interconnected. For example, since
they are highly potent, with low IC50 values, and long binding
duration, the necessary dose and intake frequency are lower
compared to normal drugs. Indeed, it has been shown that
the compliance of patients increases significantly with lower
dosing frequency, especially with once-daily dosing,12 which
can be achieved with a covalent inhibitor. It has also been
reported that covalent inhibitors have potential advantages
against resistance–prone targets. In 2013, Walter et al.13
showed that a novel covalent inhibitor, CO-1686, inhibits a
drug-resistance mutant of T790M EGFR. In this case, the
warhead is forming a covalent bond to Cys-797.
On the other hand, covalent inhibitors are often considered
to have poor selectivity due to their high reactivity. However,
several studies have shown that covalent inhibitors are
amazingly selective. In a study on quinazoline inhibitors, Zeng
et al.14 found that a targeted small covalent inhibitor
suppresses KRAS G12C, and the selectivity was higher than that
of allosteric compounds. Similarly, a study by Kempson et al.15
on Janus kinases (JAKs) showed high selectivity against JAK3
due to the addition of a covalent warhead in the compound.
The same study also showed that the compound has lower
activity towards other JAK family kinases, thus reducing the
chance of nonspecific binding. Another example in 2010, Hagel
et al.16 designed and synthesized small covalent binders
towards protease that showed inhibition towards HCV NS3/4A
viral protease (HCVP), while having weak reactivity towards
other thiols, including glutathione.
Meanwhile, covalent inhibitors have their disadvantages.
For example, they (1) may cause unexpected toxicity or
hypersensitivity, (2) may cause drug-induced toxicity, (3) may
not be suitable for targets that are rapidly turned over/
degraded by enzymes, and (4) may cause problems in
choosing the correct warhead. The recently published article
regarding covalent warheads may become a guideline,
problem, and limitation in developing a covalent warhead,
especially when it comes to the actual design, synthesis, and
in vivo studies.1 However, the increasing amount of
knowledge regarding the mechanism of action and the
reactivity of many types of warheads may facilitate the future
design of covalent inhibitors and assist in tuning their
properties to minimize their disadvantages.
4. Covalent drugs on the market and
advanced clinical trials
Among the covalent inhibitors on the market, about 28% are
used in oncology related targets, 23% are used in CNS and
cardiovascular disorders, 21% are anti-infectives (mostly the
β-lactam class of antibiotics), and about 11% are used in
gastrointestinal diseases (Fig. 4).
In the last 10 years, there are 14 newly approved covalent
drugs (Table 1). However, two of them, telaprevir and
boceprevir, were discontinued in 2014 and 2015 respectively due
to their low demand compared to newer generation of anti HCV
agents. Among these newly approved covalent drugs, there are 9
drugs with α,β-unsaturated carbonyl as their warhead. Here, a
structural analysis of the binding mode for the recently
approved covalent inhibitors is provided.
Abiraterone is a drug to treat prostate cancer. Unlike
most covalent inhibitors, there is no warhead present in
it. Instead, the nitrogen atom from pyridine ring in
Table 2 (continued)
No. Structure and name Target (therapeutic) Warhead Clinical stage
8
Tirabrutinib
BTK inhibitor α,β-Unsaturated propargylamide II
9
Spebrutinib
BTK inhibitor α,β-Unsaturated carbonyl II
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Fig. 8 Chemical structures and binding modes with the target protein: (a) AMG510 (PDB ID 6OIM) and (b) MRTX-849 (PDB ID 6UT0) binding to
Cys-12 of KRAS (G12C). Inhibitors are shown as cyan sticks and Cys-12 is shown as yellow sticks, (c) structure of CRBN–KRASG12C lead PROTAC
described by Gray et al.27
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abiraterone binds covalently to HEM-600 of the enzyme
CYP17A1 (Fig. 5).17
Telaprevir, narlaprevir and boceprevir are serine protease
inhibitors targeting, in particular, the hepatitis C virus NS3/
4A protease. All of them contain the α-ketoamide warhead.
Telaprevir binds to Ser-1139, whereas narlaprevir and
boceprevir bind to Ser-139 (Fig. 6).
Dimethyl fumarate, dacomitinib, and ibrutinib and
zanubrutinib are examples of covalent inhibitors containing
the α,β-unsaturated carbonyl warhead (Fig. 7). Dimethyl
fumarate is used for the treatment of relapse-remitting
multiple sclerosis. It binds to Cys-599 of p90 Ribosomal S6
Kinase. Dacomitinib, ibrutinib, and zanubrutinib are
anticancer drugs. Dacomitinib is an EGFR kinase inhibitor to
treat non-small cell lung cancer; it binds to Cys-797 of T790M
EGFR kinase. Ibrutinib and zanubrutinib are BTK inhibitors
used widely to treat mantle cell lymphoma. Both inhibitors
bind to Cys-481 of BTK.
Apart from the marketed covalent drugs, there are many
more inhibitors currently undergoing clinical trials in phase
II or higher. These inhibitors are aiming at cysteine residues
of the target proteins (Table 2).
5. Recent development of covalent
inhibitors
As mentioned before, there is increasing interest in
developing covalent inhibitors. Here, we highlight a few
applications of covalent inhibitors.
5.1. RAS
One of the most notorious oncology targets is still the RAS
protein. RAS is a GTPase, transmitting signals for cell growth
and division.18 For decades RAS was considered an
undruggable target.19,20 One of the first successful attempts
to target the KRAS mutant G12C was described by Shokat
et al. involving covalent inhibitors bearing the acrylamide
moiety.21 After many different attempts to tackle KRAS, in
2018 Amgen developed AMG510, a covalent inhibitor
targeting KRASG12C. Notably, AMG510 was the first
compound to undergo clinical trials after three decades of
research. MRTX-849 (developed by Mirati Therapeutics) is
also currently under clinical investigation (Fig. 8).22–24
Recently, KRAS was also explored in the field of proteolysis
targeting chimeras (PROTACs). PROTACs are an exciting new
modality of heterobifunctional molecules aiming to degrade
the protein of interest instead of inhibiting it.25,26 In 2019,
Gray et al.27 reported the development of a cereblon-based
degrader molecule library targeting KRASG12C and bearing
acrylamide warheads. Although the lead PROTAC (Fig. 8c) of
the series showed cereblon engagement in cells and bound
to KRASG12C in vitro, it was unable to effectively
polyubiquitinate endogenous KRAS and thus degradation
was not observed in pancreatic and lung cancer cells. Further
studies will be necessary to fully understand the challenges
of targeting KRAS using PROTACs.
5.2. BTK and PROTACs
In the last decade, several covalent inhibitors targeting
Bruton's tyrosine kinase (BTK) were discovered, including
ibrutinib and zanubrutinib. These compounds contain an
acrylamide warhead, targeting Cys-481 in the ATP binding
domain of BTK. Recently, these covalent kinase inhibitors
were further developed as PROTACs. In 2019, Xue et al.28
developed a series of PROTACs bearing covalent warheads.
Ibrutinib and PLS-123 as covalent inhibitors were chosen as
the backbone of the modified compounds 1 and 2 (Fig. 9).
The analogues 1 and 2 were then combined with ligands
targeting E3 ligases, either pomalidomide or VH032, through
a series of linkers and their activity towards BTK was
examined. The active group of acrylamide was also replaced
with propanamide as comparison towards covalent vs. non-
covalent inhibition. The combination between analogue 1
(ibrutinib analogue) and VH032 (PROTAC a, Fig. 10) showed
excellent results regarding BTK degradation compared to
other combinations and non-covalent PROTACs,27
highlighting a new application of covalent warheads in
protein degradation.
Conclusions
The rational development of covalent inhibitors has been
steadily increasing in the past decades. Numerous warheads
have been developed, expanding the covalent warhead
toolbox and allowing for selective targeting of specific amino
acid residues. More than 50 covalent compounds are on the
market or in advanced clinical trials. As more data emerge
regarding safety and efficacy of covalent drugs, the structure-
guided optimization and rational development will be
facilitated in the future. Thus, covalent inhibitors remain an
attractive alternative for difficult targets, including protein–
protein interactions, where selectivity may remain elusive
with non-covalent inhibitors. Moreover, the recent examples
of PROTACs bearing covalent warheads show their potential
in new modalities, whereas the development of diverse
covalent warheads allows for careful tuning of their reactivity
and selectivity.
Fig. 10 Structure of PROTAC a targeting BTK.
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